个人中心 - 老虎社区

chocolotte

IP属地：未知

帖子 · 5帖子 · 5
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- chocolottechocolotte
  ·2021-04-09
  $Star Peak Energy Transition(STPK)$to the moon[看涨] [看涨]
  2,196 1
  3
  分享
  举报
- chocolottechocolotte
  ·2021-03-13
  Time to add more?
  非常抱歉，此主贴已删除
  2,966 1
  1
  分享
  举报
- chocolottechocolotte
  ·2021-03-04
  Great news
  Ocugen stock soars after partner Bharat Biotech COVID-19 vaccine candidate shows 81% efficacy<blockquote>合作伙伴 Bharat Biotech COVID-19 候选疫苗显示出 81% 的有效率后，Ocugen 股价飙升</blockquote>
  (March 3) Shares of Histogenics soared 41.0%, after the biopharmaceutical company said its co-develo
  Ocugen stock soars after partner Bharat Biotech COVID-19 vaccine candidate shows 81% efficacy<blockquote>合作伙伴 Bharat Biotech COVID-19 候选疫苗显示出 81% 的有效率后，Ocugen 股价飙升</blockquote>
  2,726 2
  2
  分享
  举报
- chocolottechocolotte
  ·2021-02-24
  $Tiger Brokers(TIGR)$ 老虎变猫了😢
  2,743 1
  1
  分享
  举报
- chocolottechocolotte
  ·2021-02-22
  $Lockheed Martin(LMT)$ 400 soon
  1,733 评论
  点赞
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3573823256834017","uuid":"3573823256834017","gmtCreate":1610729233565,"gmtModify":1611309373446,"name":"chocolotte","pinyin":"chocolotte","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/212bdfcb3fa963bc574529a6ae74bba2","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":7,"tweetSize":5,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":2,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.07.09","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.03.01","exceedPercentage":"80.74%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.47%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":348532055,"gmtCreate":1617939149777,"gmtModify":1631886369944,"author":{"id":"3573823256834017","authorId":"3573823256834017","name":"chocolotte","avatar":"https://static.tigerbbs.com/212bdfcb3fa963bc574529a6ae74bba2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573823256834017","authorIdStr":"3573823256834017"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/STPK\">$Star Peak Energy Transition(STPK)$</a>to the moon[看涨]&nbsp;[看涨]&nbsp;<a href=\"https://laohu8.com/S/S51.SI\"></a>","listText":"<a href=\"https://laohu8.com/S/STPK\">$Star Peak Energy Transition(STPK)$</a>to the moon[看涨]&nbsp;[看涨]&nbsp;<a href=\"https://laohu8.com/S/S51.SI\"></a>","text":"$Star Peak Energy Transition(STPK)$to the moon[看涨] [看涨]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/348532055","isVote":1,"tweetType":1,"viewCount":2196,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":326387708,"gmtCreate":1615595680904,"gmtModify":1703491366150,"author":{"id":"3573823256834017","authorId":"3573823256834017","name":"chocolotte","avatar":"https://static.tigerbbs.com/212bdfcb3fa963bc574529a6ae74bba2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573823256834017","authorIdStr":"3573823256834017"},"themes":[],"title":"","htmlText":"Time to add more?&nbsp;","listText":"Time to add more?&nbsp;","text":"Time to add more?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/326387708","repostId":"2119964029","repostType":2,"isVote":1,"tweetType":1,"viewCount":2966,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":364976538,"gmtCreate":1614810459324,"gmtModify":1703481375745,"author":{"id":"3573823256834017","authorId":"3573823256834017","name":"chocolotte","avatar":"https://static.tigerbbs.com/212bdfcb3fa963bc574529a6ae74bba2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573823256834017","authorIdStr":"3573823256834017"},"themes":[],"title":"","htmlText":"Great news","listText":"Great news","text":"Great news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/364976538","repostId":"1172714394","repostType":4,"repost":{"id":"1172714394","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1614783206,"share":"https://www.laohunote.com/m/news/1172714394?lang=zh_CN&edition=full","pubTime":"2021-03-03 22:53","market":"us","language":"en","title":"Ocugen stock soars after partner Bharat Biotech COVID-19 vaccine candidate shows 81% efficacy<blockquote>合作伙伴 Bharat Biotech COVID-19 候选疫苗显示出 81% 的有效率后，Ocugen 股价飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1172714394","media":"老虎资讯综合","summary":"(March 3) Shares of Histogenics soared 41.0%, after the biopharmaceutical company said its co-develo","content":"<p>(March 3)&nbsp;Shares of <a href=\"https://laohu8.com/S/OCGN\">Histogenics</a> soared 41.0%, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 trial of its COVID-19 vaccine candidate, COVAXIN, which demonstrated efficacy of 81%.</p><p><blockquote>（3月3日）<a href=\"https://laohu8.com/S/OCGN\">组织发生学</a>该生物制药公司表示，其共同开发合作伙伴 Bharat Biotech 发布了其 COVID-19 候选疫苗科瓦克辛 3 期试验的中期分析，结果显示有效率为 81%，股价飙升 41.0%。</blockquote></p><p><img src=\"https://static.tigerbbs.com/89ef5f4dcb688419ea9c6f73c920ffb8\" tg-width=\"1068\" tg-height=\"517\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>Bharat's Phase 3 trial in India enrolled 25,800 participants aged 18 to 91, and the first interim analysis is based on 43 cases. A review of the safety database showed severe, serious and medically attended adverse events occurred at low levels and balanced between vaccine and placebo groups.</p><p><blockquote>Bharat 在印度的 3 期试验招募了 25,800 名年龄在 18 至 91 岁之间的参与者，第一次中期分析基于 43 个病例。对安全性数据库的审查显示，疫苗组和安慰剂组之间发生的严重、严重和医疗护理的不良事件水平较低且平衡。</blockquote></p><p>\"These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for EUA and approval in the United States,\" said Ocugen Chief Executive Shankar Musunuri.</p><p><blockquote>Ocugen 首席执行官 Shankar Musunuri 表示：“这些结果在一定程度上表明对快速出现的英国变种具有显着的免疫原性，代表着朝着概述美国 EUA 和批准的监管途径又迈出了一步。”</blockquote></p><p>\"COVAXIN, a whole virion based vaccine candidate, is designed to fill a significant unmet need in our national arsenal of vaccines against COVID-19.\" Ocugen's stock has skyrocketed 3,071.5% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 6.8% and the S&amp;P 500 has gained 5.6%.</p><p><blockquote>“科瓦克辛是一种基于全病毒体的候选疫苗，旨在满足我们国家针对 COVID-19 的疫苗库中尚未满足的重大需求。”过去三个月，Ocugen 的股价飙升了 3,071.5%，iShares 纳斯达克生物技术 ETF 上涨了 6.8%，标普500上涨了 5.6%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen stock soars after partner Bharat Biotech COVID-19 vaccine candidate shows 81% efficacy<blockquote>合作伙伴 Bharat Biotech COVID-19 候选疫苗显示出 81% 的有效率后，Ocugen 股价飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen stock soars after partner Bharat Biotech COVID-19 vaccine candidate shows 81% efficacy<blockquote>合作伙伴 Bharat Biotech COVID-19 候选疫苗显示出 81% 的有效率后，Ocugen 股价飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-03-03 22:53</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(March 3)&nbsp;Shares of <a href=\"https://laohu8.com/S/OCGN\">Histogenics</a> soared 41.0%, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 trial of its COVID-19 vaccine candidate, COVAXIN, which demonstrated efficacy of 81%.</p><p><blockquote>（3月3日）<a href=\"https://laohu8.com/S/OCGN\">组织发生学</a>该生物制药公司表示，其共同开发合作伙伴 Bharat Biotech 发布了其 COVID-19 候选疫苗科瓦克辛 3 期试验的中期分析，结果显示有效率为 81%，股价飙升 41.0%。</blockquote></p><p><img src=\"https://static.tigerbbs.com/89ef5f4dcb688419ea9c6f73c920ffb8\" tg-width=\"1068\" tg-height=\"517\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>Bharat's Phase 3 trial in India enrolled 25,800 participants aged 18 to 91, and the first interim analysis is based on 43 cases. A review of the safety database showed severe, serious and medically attended adverse events occurred at low levels and balanced between vaccine and placebo groups.</p><p><blockquote>Bharat 在印度的 3 期试验招募了 25,800 名年龄在 18 至 91 岁之间的参与者，第一次中期分析基于 43 个病例。对安全性数据库的审查显示，疫苗组和安慰剂组之间发生的严重、严重和医疗护理的不良事件水平较低且平衡。</blockquote></p><p>\"These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for EUA and approval in the United States,\" said Ocugen Chief Executive Shankar Musunuri.</p><p><blockquote>Ocugen 首席执行官 Shankar Musunuri 表示：“这些结果在一定程度上表明对快速出现的英国变种具有显着的免疫原性，代表着朝着概述美国 EUA 和批准的监管途径又迈出了一步。”</blockquote></p><p>\"COVAXIN, a whole virion based vaccine candidate, is designed to fill a significant unmet need in our national arsenal of vaccines against COVID-19.\" Ocugen's stock has skyrocketed 3,071.5% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 6.8% and the S&amp;P 500 has gained 5.6%.</p><p><blockquote>“科瓦克辛是一种基于全病毒体的候选疫苗，旨在满足我们国家针对 COVID-19 的疫苗库中尚未满足的重大需求。”过去三个月，Ocugen 的股价飙升了 3,071.5%，iShares 纳斯达克生物技术 ETF 上涨了 6.8%，标普500上涨了 5.6%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172714394","content_text":"(March 3) Shares of Histogenics soared 41.0%, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 trial of its COVID-19 vaccine candidate, COVAXIN, which demonstrated efficacy of 81%.Bharat's Phase 3 trial in India enrolled 25,800 participants aged 18 to 91, and the first interim analysis is based on 43 cases. A review of the safety database showed severe, serious and medically attended adverse events occurred at low levels and balanced between vaccine and placebo groups.\"These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for EUA and approval in the United States,\" said Ocugen Chief Executive Shankar Musunuri.\"COVAXIN, a whole virion based vaccine candidate, is designed to fill a significant unmet need in our national arsenal of vaccines against COVID-19.\" Ocugen's stock has skyrocketed 3,071.5% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 6.8% and the S&P 500 has gained 5.6%.","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":2726,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":363545169,"gmtCreate":1614158890851,"gmtModify":1634550952436,"author":{"id":"3573823256834017","authorId":"3573823256834017","name":"chocolotte","avatar":"https://static.tigerbbs.com/212bdfcb3fa963bc574529a6ae74bba2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573823256834017","authorIdStr":"3573823256834017"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>&nbsp; 老虎变猫了😢","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>&nbsp; 老虎变猫了😢","text":"$Tiger Brokers(TIGR)$ 老虎变猫了😢","images":[{"img":"https://static.tigerbbs.com/3de6eb5b4f01f1d52839ed38b9c26ef2","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/363545169","isVote":1,"tweetType":1,"viewCount":2743,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":369121196,"gmtCreate":1614009272815,"gmtModify":1631886998604,"author":{"id":"3573823256834017","authorId":"3573823256834017","name":"chocolotte","avatar":"https://static.tigerbbs.com/212bdfcb3fa963bc574529a6ae74bba2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573823256834017","authorIdStr":"3573823256834017"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/LMT\">$Lockheed Martin(LMT)$</a>&nbsp;400 soon","listText":"<a href=\"https://laohu8.com/S/LMT\">$Lockheed Martin(LMT)$</a>&nbsp;400 soon","text":"$Lockheed Martin(LMT)$ 400 soon","images":[{"img":"https://static.tigerbbs.com/4a4ac8d2ccf19973cb81fe2953c1019f","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/369121196","isVote":1,"tweetType":1,"viewCount":1733,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}